Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drug developer Human Genome Sciences
So what: Next week, a panel will meet to recommend to the Food and Drug Administration whether Benlysta -- developed by Human Genome along with partner GlaxoSmithKline
Now what: There's no doubt that the Benlysta case is high stakes for Human Genome -- not to mention Glaxo. Bloomberg recently estimated that the drug could bring in more than $2.1 billion in sales by 2014, and its approval could spark takeover offers for Human Genome from Glaxo, along with other giants like Amgen
Want to keep up to date on Human Genome Sciences? Add it to your watchlist by clicking here. Or are you following Benlysta from the Glaxo side? Go ahead and put Glaxo on your watchlist by clicking here.